chromium trichloride
Approved
Jun 26, 1986
Chromium(III) chloride (also called chromic chloride) is an inorganic chemical compound with the chemical formula CrCl3. This crystalline salt forms several hydrates with the formula CrCl3·nH2O, among which are hydrates where n can be 5 (chromium(III) chloride pentahydrate CrCl3·5H2O) or 6 (chromium(III) chloride hexahydrate CrCl3·6H2O). The anhydrous compound with the formula CrCl3 are violet crystals, while the most common form of the chromium(III) chloride are the dark green crystals of hexahydrate, CrCl3·6H2O. Chromium chlorides find use as catalysts and as precursors to dyes for wool. — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 4 marketing orgs
Earliest trial started Feb 20, 2017 (NCT03038282)
Timeline
Indications
Approved for
Mechanism of action
- chromiumSupplementation
chromium supplementation
Approval history
- approvedPriority reviewJun 26, 1986
Chemistry & pharmacology
- Mol. weight
- 158.36 g/mol
- Chirality
- Achiral Molecule
- Inorganic
- Yes
- Polymer
- No
- Delivery
- Parenteral
- Availability
- Prescription Only
Oral
No
Parenteral
Yes
Topical
No
Sources
- WikipediaChromium(III) chloride ↗
- ChEMBLCHEMBL1200528 ↗
Also known as
- anhydrous chromium(iii) chloride
- anhydrous chromium(iii) chloride
- chromic chloride
- chromic chloride
- chromic chloride
- chromic chloride
- chromic chloride
- chromic chloride
- chromic chloride
- chromic chloride
- chromic chloride, 51cr-labeled
- chromic chloride anhydrous
- chromic chloride hexahydrate
- chromic chloride hexahydrate
- chromic trichloride
- chromium(3+) trichloride
- chromium(3+) trichloride
- chromium chloride
- chromium chloride
- chromium chloride
- chromium chloride
- chromium chloride (crcl3)
- chromium dichloride
- chromium(iii) chloride
- chromium(iii) chloride
- chromium trichloride
- chromium trichloride
- chromium trichloride
- chromium trichloride
- chromous chloride
- puratronic chromium chloride
- trichlorochromium
- trichlorochromium
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03038282 | N/A | Feb 20, 2017 | Metabolic Therapy Inc., The University of Texas, Dallas |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Metabolic Therapy Inc. | For profit | 1 | 1 | 1 | 2017 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 0 | 1 | 2017 |
Marketing (5)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Abraxis | For profit | NDA2 | May 5, 1987 |
| Apicore | For profit | MKTG | Nov 18, 2024 |
| Hospira | For profit | NDA2 | Jun 26, 1986 |
| Hospira | For profit | NDA | Jun 26, 1986 |
| Somerset Pharmaceuticals | For profit | MKTG | Nov 18, 2024 |